(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Development and use of antibodies that target phosphatidylserine for the treatment of cancer

What is it about?

Phosphatidylserine (PS) is an immunosuppressive lipid. Antibodies that target PS can reduce PS-mediated immune suppression and facilitate an anti-tumor immune response. The key experiments in understanding the function of PS targeting antibodies are described and examples of immune modulation in tumor-bearing animals after treatment with PS targeting antibodies are discussed.

Why is it important?

Immune oncology strategies to treat cancer are changing how cancer patients are treated today. However, a significant fraction of cancer patients do not respond to current therapies. Identification of avenues to enhance the activity of current and future immune focused anti-cancer strategies has the potential to significantly improve patient outcome.

Read more on Kudos…
The following have contributed to this page:
rolf brekken
' ,"url"));